Gastrointestinal mastocytosis carries a significant risk of bone marrow involvement, even when patients are otherwise asymptomatic for systemic mastocytosis (SM), according to a recent study published in Laboratory Investigation.
This rare condition occurs when abnormal mast cells accumulate in the digestive tract. While the gastrointestinal tract is one of the most common areas affected by SM, doctors are still learning how an initial finding in the gut might predict the overall course of the disease and the risk of it affecting other parts of the body.
The study analyzed 28 cases of gastrointestinal mastocytosis to better understand how this diagnosis affects a patient’s long-term outlook. Researchers categorized patients into three groups to compare their experiences:
- Group 1 had a known history of SM or cutaneous mastocytosis and existing symptoms.
- Group 2 had no prior diagnosis, but did previously present with symptoms that were later linked to the condition.
- Group 3 had neither a history of the disease nor any mastocytosis-related symptoms.
While endoscopies for patients in Groups 1 and 2 were largely symptom-driven, the condition in Group 3 was often discovered by chance during routine screening colonoscopies. Although these asymptomatic patients appeared healthy and had significantly lower tryptase levels compared to those in the first two groups, the underlying risks still persisted.
While every patient in Groups 1 and 2 showed bone marrow involvement, the findings in Group 3 were also significant; despite having no symptoms, 57% of these patients showed confirmed bone marrow involvement.
The clinical progression of the disease further highlighted the divide between the groups. Among symptomatic patients, the risk was notably higher, with 38% to 43% progressing to advanced SM (AdvSM), a severe category of the disease that includes aggressive SM and mast cell leukemia. Consequently, nearly half of these patients (up to 50%) required intensive cytoreductive therapy, and each group saw a disease-related death.
In contrast, while the asymptomatic group faced a lower risk of advanced progression (8%) and required intensive treatment less frequently (8%), their long-term outlook still required vigilance: 63% experienced a recurrence in the gut, and one patient even progressed to AdvSM despite never developing symptoms.
Alongside these clinical parameters, the KIT D816V mutation was detected in all groups, including those without symptoms. While the mutation was most prevalent in those with a known history (80%), it was also detected in 29% of Group 2 and 22% of Group 3.
“[Gastrointestinal mastocytosis] as an initial diagnosis, even in asymptomatic patients, carries a substantial risk of BM involvement and a small but notable risk of progression to AdvSM,” authors concluded. They emphasized that a thorough medical assessment is essential to correctly identify the disease and create a treatment plan, even if a patient feels healthy or has no history of the condition.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
